Inhibitex begins Phase I/II

Inhibitex (Alpharetta, Ga.) began a 24-patient Phase I/II trial of its intravenous human immune globulin against Staphylococcus aureus (SA- IGIV) to treat S. aureus infections in patients receiving he...